Durvalumab Approved for Endometrial Cancer

  Published 9 months ago

Durvalumab combo treats advanced endometrial cancer; AstraZeneca leads oncology innovation.

  • Durvalumab plus chemo for first-line advanced/recurrent pMMR endometrial cancer.
  • Maintenance therapy combines Durvalumab and olaparib post-chemotherapy.
  • AstraZeneca focuses on oncology, cardiovascular, renal, and rare diseases.

You might like these

Auto Stocks Rev Up on Strong July Sales

Kolte-Patil Developers Reports Strong FY25 Growth

JD Cables Wins Rs9.8 Crore XLPE Deal

Century Legend Acquires PLTR Shares in Strategic Move

KEC Posts Strong Q1 with 41% PBT Jump

India Q4 2024-25 Earnings: Slower Sales, Stronger Profits

Borosil Q1 FY26 Financial Highlights

News that matters the most ⚡